|
|||||
|
|
The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies |
|
| Authors: | Barry Gumbiner Tenshang Joh Alicia M. Vana Stephan Billotte Pamela D. Garzone |
| Affiliation: | Pfizer Inc., South San Francisco and San Diego, CA, USA |
| Abstract: | |
| Keywords: | bococizumab humanized monoclonal antibody hypercholesterolemia low‐density lipoprotein cholesterol phase I clinical trial proprotein convertase subtilisin/kexin type 9 inhibitor |